# LifeStance Health account plan

> LifeStance Health is a US outpatient mental health platform with 8,863 clinicians and FY2025 revenue of $1,424.3 million.

## At a glance

LifeStance Health Group (Nasdaq: LFST), based in Scottsdale, Arizona, is one of the largest US outpatient mental health platforms, offering psychiatric treatment, psychological and neuropsychological testing and therapy in person and virtually to children, adolescents and adults. In 2025 its employed clinicians treated more than 1.0 million unique patients through approximately 9.0 million visits, and about 90% of revenue came from commercial in-network payors. FY2025 revenue was $1,424.3 million (+14%), with net income of $9.7 million and Adjusted EBITDA of $157.7 million; the company had about 10,961 employees. At September 30, 2026 it employed 8,863 clinicians, and its former private equity owners TPG and Summit held about 25.3%, so it is no longer a Nasdaq controlled company.

## Strategic priorities

- **Clinician growth and productivity**: Clinicians reached 8,863 at September 30, 2026 (+11%), and visits per average clinician rose 5% in Q3 2026; management says it uses about 70% of the time clinicians make available and aims to improve retention by five plus percent over the long run.
- **New EHR rollout**: A new electronic health record is being tested through year end, then rolled out in phases through 2027, starting with one state; implementation is expected to cost about $20-30 million and trim 2027 revenue growth by about one to two percentage points.
- **Specialty services**: Specialty revenue (mostly neuropsych testing, plus TMS and Spravato) of about $50 million last year is expected to grow about 40% to roughly $70 million in 2026; 37 centers offer TMS and 25 Spravato.
- **Geographic expansion**: LifeStance is present in roughly half of the 150 largest US markets; it plans one to two tuck-in acquisitions per quarter through 2027 and assumes 20-30 de novo centers for 2027, after 20 new centers year to date in 2026.
- **AI and digital**: AI is used in new-patient phone booking, clinical documentation, the contact center and revenue cycle management, alongside a care matching pilot to be rolled out to all state practices.
- **Margin expansion**: The long-term target is an Adjusted EBITDA margin of 15-20%, with 20% not a ceiling, and mid-teens revenue growth; an updated long-term view is planned for the beginning of 2028.

## Latest results

In Q3 2026 revenue rose 25% to $455.9 million on 2.7 million visits (+17%) and total revenue per visit of $170 (+7%). Net income was $22.4 million against $1.1 million a year earlier, Center Margin $161.4 million (35.4% of revenue) and Adjusted EBITDA $68.4 million (+70%, 15.0% margin). Nine-month revenue was $1,294.7 million (+24%) and operating cash flow $170.0 million. Full-year 2026 guidance was raised to revenue of $1.741-1.761 billion, Center Margin of $599-613 million and Adjusted EBITDA of $242-250 million; Q4 2026 guidance is revenue of $446-466 million.

## Investments and deals

- **Electronic health record replacement**: A new EHR vendor was chosen; implementation runs through 2026 and the transition through 2027, with $20-30 million of cash use, mostly capitalized or adjusted.
- **Tuck-in acquisitions**: Four outpatient mental health practices acquired in the first nine months of 2026 for $14.1 million aggregate consideration, including an Iowa tuck-in in Q3 that took the footprint to 34 states.
- **Share buybacks**: 15 million shares repurchased for $122.4 million in the first nine months of 2026; a new $100.0 million program was approved on August 5, 2026, with $75.4 million remaining.
- **Second-half reinvestment**: First-half upside is being reinvested in patient acquisition, tech and AI, clinical excellence teams, clinician compensation and benefits, and a refresh of some centers in Q4 2026.

## Challenges and risks

- **Payor concentration and rates**: About 90% of revenue comes from commercial in-network payors, and UnitedHealthcare (14%) and Elevance Health (15%) each exceed 10% of revenue; in 2025 total revenue per visit fell on a single payor rate decrease.
- **Clinician recruitment and retention**: Competition for clinicians is intense, and retention is weakest among new clinicians; LifeStance holds a low single-digit share of the total clinician population.
- **Internal control weaknesses**: Disclosure controls remained not effective at September 30, 2026 because of material weaknesses first identified for 2019, though remediation is advancing.
- **EHR transition disruption**: Management expects the new EHR to cause a short-term blip in productivity and to reduce 2027 revenue growth toward the lower end of the mid-teens range.
- **Regulatory and privacy exposure**: Corporate-practice-of-medicine laws underpin 392 of 572 centers run as supported practices, and a privacy class action over pixel tracking awaits settlement approval.

## What leadership says

> "The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations" — Dave Bourdon, Chief Executive Officer, Q3 2026 results press release, November 5, 2026

> "mental health care is entering its next phase where differentiation will increasingly be driven by outcomes, not just access." — David Bourdon, Chief Executive Officer, Q2 2026 earnings call, August 6, 2026

> "We're utilizing right now about 70% of the time that clinicians give us." — David Bourdon, Chief Executive Officer, Q2 2026 earnings call, August 6, 2026

> "We expect margins to keep expanding in 2027 and beyond" — Ryan McGroarty, Chief Financial Officer, Q3 2026 earnings call, November 5, 2026


## Where a supplier can help

- **EHR migration support**: The phased EHR rollout through 2027 (data conversion, workflow standardization, reconnecting point solutions) creates demand for implementation, integration and training partners.
- **Patient access and scheduling**: With clinicians' available time about 70% used, tools for new-patient conversion, scheduling optimization and care matching tie directly to the productivity priority.
- **Revenue cycle and payor work**: Payor concentration and annual rate negotiations, supported by outcomes data, point to revenue cycle automation, analytics and outcome measurement suppliers.
- **Clinician recruiting and retention**: Clinician growth is the main revenue driver, so recruiting, credentialing, benefits and retention solutions address a core challenge.
- **Center build-out and specialty equipment**: 20-30 new centers a year, center refreshes and the expansion of TMS and Spravato sites need real estate, fit-out and specialty treatment suppliers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1845257/000119312526071462/lfst-20251231.htm)

Annual report · 2026-02-25

- LifeStance Health Group (Nasdaq: LFST, Scottsdale, Arizona) is one of the largest US outpatient mental health platforms: 8,040 employed licensed clinicians (psychiatrists, APNs, psychologists, therapists) in 33 states and 572 centers at December 31, 2025, with a hybrid in-person and virtual model.
- 2025 scale: more than 1.0 million unique patients and approximately 9.0 million visits; 87% of patients had two or more visits; about 10,961 employees in total.
- FY2025 total revenue $1,424.3 million (+14%), driven by a net increase of 657 clinicians and 1.1 million more visits (+14%); total revenue per visit (TRPV) fell on a single payor rate decrease.
- Profitability turned: income from operations $24.1 million (vs. a $31.6 million loss in 2024), net income $9.7 million (vs. a $57.4 million loss), Center Margin $461.1 million and Adjusted EBITDA $157.7 million (vs. $119.7 million).
- Revenue is fee-for-service per visit and 90% from commercial in-network payors (5% government, 4% self-pay, 1% non-patient); UnitedHealthcare (14%) and Elevance Health (15%) each exceed 10% of revenue, the top risk being payor reimbursement rates.
- Growth playbook: in-house clinician recruiting, new centers, selective acquisitions of independent practices, national payor contracts and referral partnerships with primary care and specialist physicians (over 13 integrated care programs).
- Cash flow from operations $146.2 million, capex $36.1 million, cash $248.6 million and $282.8 million outstanding under the 2024 Credit Agreement (Capital One-led term loan plus $100.0 million revolver).
- A single reportable segment, mental health services, entirely in the US; 392 of the 572 centers are supported practices run under management services contracts because of corporate-practice-of-medicine laws.
- Governance: CEO David Bourdon, CFO Ryan McGroarty, Executive Chairperson Kenneth Burdick; TPG, Silversmith and Summit owned about 53.7% at year end (controlled company); material weaknesses in internal control remained unremediated.

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1845257/000119312526449746/lfst-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 total revenue $455.9 million (+25%) and nine-month revenue $1,294.7 million (+24%), driven by a net increase of 867 clinicians (organic hiring and acquisitions), higher clinician productivity and higher TRPV from modest payor rate increases.
- Clinicians employed reached 8,863 at September 30, 2026; Q3 visits 2.7 million and nine-month visits 7.8 million.
- Q3 income from operations $33.1 million (vs. $7.4 million), net income $22.4 million (vs. $1.1 million), Center Margin $161.4 million, Adjusted EBITDA $68.4 million (vs. $40.2 million).
- Nine-month operating cash flow $170.0 million (vs. $88.6 million); capex $37.4 million; acquisitions $9.6 million.
- Four outpatient mental health practices acquired in nine months for $14.1 million aggregate consideration (cash $10.1 million plus contingent consideration).
- Share buybacks: 15 million shares repurchased for $122.4 million in nine months; a new $100.0 million program approved August 5, 2026, with $75.4 million remaining.
- Cash $218.8 million, $271.9 million outstanding under the 2024 Credit Agreement, covenants met.
- TPG and Summit now hold about 25.3%; LifeStance is no longer a Nasdaq controlled company. Material weaknesses in internal control persist, with remediation advancing; costs for a new electronic health resources system are being incurred.

### [LifeStance Reports Strong Third Quarter 2026 Financial Results and Raises Full Year Outlook (press release, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1845257/000119312526447943/lfst-ex99_1.htm)

Interim report · 2026-11-05

- Q3 2026 revenue $455.9 million (+25%); clinician base up 11% to 8,863 with a sequential net increase of 321; visits up 17% to 2.7 million.
- Net income $22.4 million (vs. $1.1 million); Center Margin $161.4 million (35.4% of revenue, vs. 32.0%); Adjusted EBITDA $68.4 million (+70%, 15.0% margin vs. 11.1%).
- Q3 operating cash flow $37.0 million and Free Cash Flow $22.4 million; cash $218.8 million and net long-term debt $255.5 million.
- FY2026 guidance raised: revenue $1.741-1.761 billion, Center Margin $599-613 million, Adjusted EBITDA $242-250 million.
- Q4 2026 guidance: revenue $446-466 million, Center Margin $149-163 million, Adjusted EBITDA $56-64 million.
- CEO Dave Bourdon credits execution across the business, positive patient outcomes for TMS and Spravato, and investments including the implementation of a new EHR.
- LifeStance and its supported practices employ over 8,800 clinicians across 35 states and more than 575 centers; nine-month share repurchases totaled $122.4 million.

### [LifeStance Health Q3 2026 Earnings Call Transcript](https://www.earningswhispers.com/transcript/LFST/Q32026)

Executive talk · Dave Bourdon, Chief Executive Officer (with Ryan McGroarty, Chief Financial Officer) · 2026-11-05

- Second consecutive quarter with revenue growth of 25% or more and Adjusted EBITDA margins of 15%; full-year guidance raised again across all metrics (revenue $1.741-1.761 billion, Adjusted EBITDA $242-250 million, implying about 23% growth and a 14% margin at the midpoints).
- Q3: 321 net clinician adds to 8,863 (+11%), visits 2.7 million (+17%), TRPV $170 (+7%, mainly payer rate increases), visits per average clinician +5%.
- New EHR: testing through year end, then a phased rollout through 2027 starting with one state of a couple hundred clinicians; expected to cut 2027 revenue growth by about one to two percentage points, so 2027 growth toward the lower end of the long-term mid-teens range; implementation cost about $20-30 million.
- Specialty services: about $50 million of revenue last year (mostly neuropsych testing), growing about 40% to roughly $70 million in 2026 via TMS and Spravato; 37 centers offer TMS and 25 Spravato, added at about a handful per quarter.
- Outcomes data: 74% of Spravato and 61% of TMS patients had clinically meaningful depression reductions; used in payer discussions on coverage and rates.
- Expansion: one Iowa tuck-in in Q3 (now 34 states), one to two tuck-ins per quarter expected through 2027; 8 new centers in Q3 and 20 year to date, a 20-30 de novo pace assumed for 2027.
- Long-term: Adjusted EBITDA margin 15-20% with 20% "not representing a ceiling"; updated long-term view at the beginning of 2028. Clinician retention stable; goal to improve it by five plus percent.

### [LifeStance (LFST) Q2 2026 Earnings Call Transcript](https://www.webull.com/news/15359389277447168)

Executive talk · David Bourdon, Chief Executive Officer (with Ryan McGroarty, Chief Financial Officer) · 2026-08-06

- Q2 2026 revenue $435 million (+26%), visits 2.6 million (+19%), TRPV $167 (+6%), visits per average clinician +7% for a third straight quarter; 193 net clinician adds to 8,542 (+11%).
- Center Margin $153 million (+41%, 35.2%), Adjusted EBITDA $66 million (+94%, 15.2% margin), net income $24 million, free cash flow $88 million.
- FY2026 guidance raised to revenue $1.685-1.725 billion, Center Margin $570-594 million, Adjusted EBITDA $215-235 million; TRPV outlook lifted to mid-single digits.
- New $100 million buyback after deploying $97 million of the first program; $49 million repurchased in Q2.
- Second-half reinvestment in patient acquisition, tech and AI, clinical excellence teams and clinician compensation and benefits.
- Geographic white space: presence in roughly half of the 150 largest US markets; tuck-in acquisitions preferred to open new geographies, de novo otherwise; organic growth in existing markets.
- Clinicians use about 70% of the time they make available; specialty services (neuropsych testing, TMS, Spravato) to grow faster than the core; Bourdon sees care "entering its next phase" driven by outcomes.

### [LifeStance (LFST) Q4 2025 Earnings Call Transcript](https://www.aol.com/articles/lifestance-lfst-q4-2025-earnings-150932369.html)

Executive talk · David Bourdon, Chief Executive Officer (with Ryan McGroarty, Chief Financial Officer, and Ken Burdick, Executive Chairman) · 2026-02-25

- 2025: revenue $1,424 million (+14%), Adjusted EBITDA $158 million (+32%, 11.1% margin), first full year of positive net income as a public company, one year early; free cash flow $110 million (2024: $86 million).
- Q4 2025: revenue $382 million (+17%), visits 2.4 million (+18%), visits per average clinician +7%, Adjusted EBITDA margin 12.8%, a record as a public company; clinicians 8,040 (+9%).
- 2026 guidance: revenue $1.615-1.655 billion, Center Margin $526-550 million, Adjusted EBITDA $185-205 million; 20-30 new centers; first $100 million share buyback announced.
- Long-term algorithm: mid-teens revenue growth (low-to-mid single-digit rate plus low double-digit volume), Center Margin to the mid-thirties, mid-teens Adjusted EBITDA margin by fiscal 2028.
- New best-in-class EHR chosen: implementation in 2026, transition in 2027, $20-30 million cash use; AI used in phone booking, documentation and revenue cycle; care matching pilot to roll out to all state practices.
- Specialty revenue targeted at $70 million in 2026 (about 40% up from about $50 million), mainly Spravato and TMS; payer contract count cut by about 50% over three years.
- Ken Burdick moves from Executive Chair to Non-Executive Chair; patients acquired for about 2% of revenue; tuck-in M&A targeted down-market for new geographies.

## Questions about LifeStance Health

### What does LifeStance Health do?

LifeStance provides outpatient mental healthcare in person and virtually, including psychiatric treatment, psychological and neuropsychological testing and therapy, through employed clinicians. It operates more than 575 centers across 35 states, per its Q3 2026 release.

### What is LifeStance Health's revenue?

FY2025 revenue was $1,424.3 million, up 14%. For 2026 the company guides to revenue of $1.741-1.761 billion, after Q3 2026 revenue of $455.9 million (+25%).

### How many employees does LifeStance have?

LifeStance had about 10,961 employees at the end of 2025, and employed 8,863 licensed clinicians at September 30, 2026.

### What is LifeStance's growth strategy?

It grows through in-house clinician recruiting, new centers, tuck-in acquisitions of independent practices and payor and referral partnerships, while expanding specialty services such as TMS and Spravato.

### Who leads LifeStance Health?

David Bourdon is Chief Executive Officer and Ryan McGroarty is Chief Financial Officer; Ken Burdick moved from Executive Chair to Non-Executive Chair.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
